Plasma cyclic nucleotide levels in acute leukemia patients

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Extracellular cyclic nucleotides are investigated as potential tumor markers.
• Acute leukemia presents challenges in monitoring disease status and treatment efficacy.

Purpose of the Study:

• To assess the clinical utility of plasma cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) as tumor markers in acute leukemia.
• To correlate cyclic nucleotide levels with disease stage and treatment response.

Main Methods:

• Plasma cAMP and cGMP levels were measured in 70 healthy individuals and 173 acute leukemia patients.
• Measurements were taken across different stages of the disease, including diagnosis, active disease, remission, and relapse.

Main Results:

• Plasma cAMP levels were comparable between leukemic and normal subjects.
• A subset of 48 patients with active disease, newly diagnosed, or relapsed had below-normal cAMP levels and poor chemotherapy response.
• Plasma cGMP levels were significantly elevated in untreated acute leukemia patients.
• cGMP levels normalized in patients achieving complete remission.
• cGMP levels promptly increased to pretreatment levels upon relapse.

Conclusions:

• Plasma cGMP determination shows potential as a valuable tool for monitoring acute leukemia treatment response.
• While plasma cAMP levels did not consistently correlate with disease status, decreased levels may indicate poor prognosis.
• Further investigation into cyclic nucleotide dynamics could refine leukemia management strategies.